GRGrifols GRFS · NASDAQ
$7.64 +1.33% (+$0.10)
- Market cap
- 5.69B €
- Enterprise value
- 13.7B €
- P/E
- 12.6x
- Forward P/E
- 9.7x
- PEG
- 0.1x
- P/S
- 0.8x
- P/FCF
- 7.9x
- EV/EBITDA
- 7.8x
- ROIC
- 5.5%
- Bruto marža
- 37.2%
- Neto marža
- 6.1%
- Dividend yield
- 1.25%
- Payout ratio
- 15.7%
- Neto dolg/EBITDA
- 4.6x
- Beta
- 1.19
- Free float
- 98.7%
O podjetju
Grifols, S.A. is a global Spanish pharmaceutical and biotechnology company specializing in the production of plasma-derived medicines and healthcare products. The company focuses on producing immunoglobulins, albumin, and other plasma-based products that are essential for the treatment of various diseases, including immunological and neurological disorders. Grifols also develops diagnostic tools and systems for hospitals and clinics. The company has a broad global presence and operates in over 30 countries worldwide.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jose Ignacio Abia Buenache
Employees
25,258
Headquarters
Barcelona
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke